PDF
(Download)
|
- Ashwagandha (Withania somnifera)
- Pain
- Inflammation
|
Date:
09-15-2014 | HC# 041465-504
|
Re: Ashwagandha Extract Relieves Acute Thermal Pain in Human Subjects
Usharani
P, Nalini P, Manjunath N K, SunilKumarReddy K. Evaluation of the analgesic
activity of standardized aqueous extract of Withania
somnifera in healthy human volunteers using Hot Air Pain Model. Research Journal of Life Sciences. May 2013;1(2):1-6.
In
health care, pain management may present challenges. Pain medications such as
non-steroidal anti-inflammatory drugs (NSAIDs), although effective, cause a
diverse array of adverse side effects (ASEs). Among its many applications, ashwagandha
(Withania somnifera) is used in
Ayurvedic medicine for treating painful conditions such as osteoarthritis and
rheumatism. Clinical and in vivo studies have shown this botanical to have anti-inflammatory
activity. This randomized, double-blind, placebo-controlled, crossover study
investigated whether ashwagandha aqueous extract consumption alleviates pain in
subjects using a hot air analgesiometer, an instrument that delivers
consistent, superficial thermal pain.
The
study took place at Nizam's Institute of Medical Sciences, Hyderabad, India.
Potential subjects were enrolled based on physical and clinical examinations,
as well as medical history. Blood parameters were used to assess normal organ
function, and subjects were familiarized with the pain evaluation technique
before the study began. Male subjects from 18-40 years old with a body mass
index (BMI) ranging from 19.5-25.9 kg/m2 were included. Subjects
were not allowed to use pain medication, anti-inflammatory drugs, or fever-reducing
medications within 2 weeks prior to the study. If subjects had general health
problems (including drug abuse), had abnormal lab tests, or consumed
antioxidants or over-the-counter medications in the prior 2 weeks or
"investigational" drugs within 3 months prior to the study, they were
excluded.
Treatment
consisted of 2 capsules of 500 mg each of SENSORIL® (Natreon, Inc.; New
Brunswick, New Jersey) or 2 capsules of placebo. SENSORIL consisted of a water
extract of ashwagandha root and leaf and included approximately 15.7% withanolide glycosides
(thought to be the bioactive compounds), 40.2% oligosaccharides, and 0.24% withaferin-A.
Placebo content was not described. On study days, subjects arrived at the study
location in the morning, were given a light breakfast, and were instructed to
sit for 30 minutes before the study's start.
Subjects
were then blindfolded and inserted their non-dominant arm into the hot air
analgesiometer. After the heat was turned on and pain was sensed, subjects
raised a finger on the other hand, and the procedure was stopped. Pain
threshold was calculated as time in seconds from the initiation of the
procedure to pain detection, and this test was repeated with 5 minute intervals
3 times total. Following these tests, treatment was randomly administered
(either SENSORIL or placebo), and subjects remained sitting upright for 2 hours
or more. After 3 hours, the pain test was administered again and laboratory
parameters analyzed. This study day was conducted again with the alternate
treatment after 2 weeks of washout. [Note: The text gives the washout period as
2 weeks; however, the abstract says the washout time period was 10-14 days.]
Subjects were instructed to mention any ASEs.
In
total, of the 14 subjects recruited, 2 were excluded due to elevated liver
function results at screening, with 12 subjects completing the study. Average
age of the subjects was 35.28 ± 3.31 years; average subject BMI was 21.33 ±
1.012 kg/m2. Following the consumption of ashwagandha, the pain
threshold was increased significantly from 43.99 ± 6.79 seconds to 49.89 ± 7.07
seconds (P<0.001). In contrast, after placebo, pain threshold increased from
43.79 ± 6.19 seconds to 44.28 ± 9.19 seconds. The amount of increase in pain
threshold after ashwagandha consumption was significantly greater than that
following the placebo (12.85% vs. 0.4%, P<0.001). It is stated that
compliance was "excellent," and no abnormalities were detected in
laboratory parameters.
This
study shows that the ashwagandha product SENSORIL was effective in extending
the pain threshold for the particular acute thermal pain model used here. It is
suggested that the bioactivity observed in other clinical studies with this
botanical for treating chronic pain may be due to anti-inflammatory activity. Future
studies need to confirm these findings and focus on this outcome of providing
long-term pain relief safely.
—Amy C. Keller,
PhD
|